WO1996000087A3 - Materiel de preciblage et nouveaux conjugues de preciblage - Google Patents

Materiel de preciblage et nouveaux conjugues de preciblage Download PDF

Info

Publication number
WO1996000087A3
WO1996000087A3 PCT/EP1995/002425 EP9502425W WO9600087A3 WO 1996000087 A3 WO1996000087 A3 WO 1996000087A3 EP 9502425 W EP9502425 W EP 9502425W WO 9600087 A3 WO9600087 A3 WO 9600087A3
Authority
WO
WIPO (PCT)
Prior art keywords
pretargeting
conjugates
kit
targeting
novel
Prior art date
Application number
PCT/EP1995/002425
Other languages
English (en)
Other versions
WO1996000087A2 (fr
Inventor
Ebo Sybren Bos
Franciscus Michael Kaspersen
Original Assignee
Akzo Nobel Nv
Ebo Sybren Bos
Franciscus Michael Kaspersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Ebo Sybren Bos, Franciscus Michael Kaspersen filed Critical Akzo Nobel Nv
Priority to AU28871/95A priority Critical patent/AU2887195A/en
Publication of WO1996000087A2 publication Critical patent/WO1996000087A2/fr
Publication of WO1996000087A3 publication Critical patent/WO1996000087A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de préciblage de composés thérapeutiques ou diagnostiques permettant de cibler des cellules dans le corps, ainsi qu'un matériel destiné audit procédé. De préférence, le ciblage s'effectue par un anticorps spécifique. La liaison entre la fraction de ciblage préinjectée et la fraction effectrice s'établit à l'aide d'un 'doigt' de zinc et de la séquence de nucléotides parente de celui-ci, conjuguée à la fraction de ciblage ou effectrice. L'invention concerne également des conjugués de 'doigts' de zinc ainsi que des composés thérapeutiques ou diagnostiques.
PCT/EP1995/002425 1994-06-24 1995-06-22 Materiel de preciblage et nouveaux conjugues de preciblage WO1996000087A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28871/95A AU2887195A (en) 1994-06-24 1995-06-22 Kit for pretargeting and novel pretargeting conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201826 1994-06-24
EP94201826.8 1994-06-24

Publications (2)

Publication Number Publication Date
WO1996000087A2 WO1996000087A2 (fr) 1996-01-04
WO1996000087A3 true WO1996000087A3 (fr) 1996-03-07

Family

ID=8216990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002425 WO1996000087A2 (fr) 1994-06-24 1995-06-22 Materiel de preciblage et nouveaux conjugues de preciblage

Country Status (2)

Country Link
AU (1) AU2887195A (fr)
WO (1) WO1996000087A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020082979A (ko) * 2001-04-24 2002-11-01 이명철 질 수축 압력측정기
CN104220458B (zh) * 2012-02-24 2018-08-14 阿特根公司 结合有含半胱氨酸残基的基序的修饰抗体，含该修饰抗体的修饰抗体-药物缀合物以及其制造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008220A1 (fr) * 1989-12-01 1991-06-13 Gunnar Houen Procede de synthese regulee par etapes d'especes chimiques, notamment de peptides, de produits couples obtenus selon le procede, et emploi de ces produits couples, par exemple en tant que vaccins
WO1992011365A1 (fr) * 1990-12-21 1992-07-09 The Rockefeller University Facteur de transcription enrichi par extraits hepatiques
WO1993017707A1 (fr) * 1992-03-04 1993-09-16 Akzo N.V. PRE-CIBLAGE DE PAIRE DE LIAISON $i(IN VIVO)
EP0650735A2 (fr) * 1993-07-09 1995-05-03 Akzo Nobel N.V. Kit et méthode de préciblage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008220A1 (fr) * 1989-12-01 1991-06-13 Gunnar Houen Procede de synthese regulee par etapes d'especes chimiques, notamment de peptides, de produits couples obtenus selon le procede, et emploi de ces produits couples, par exemple en tant que vaccins
WO1992011365A1 (fr) * 1990-12-21 1992-07-09 The Rockefeller University Facteur de transcription enrichi par extraits hepatiques
WO1993017707A1 (fr) * 1992-03-04 1993-09-16 Akzo N.V. PRE-CIBLAGE DE PAIRE DE LIAISON $i(IN VIVO)
EP0650735A2 (fr) * 1993-07-09 1995-05-03 Akzo Nobel N.V. Kit et méthode de préciblage

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; *
HSIEH J. C. ET AL.: "RECEPTOR MEDIATED GENOMIC ACTION OF THE 1,25 (OH)2D3 HORMONE: EXPRESSION OF THE HUMAN VITAMIN D RECEPTOR IN E. COLI.", J. STEROID BIOCHEM. MOL. BIOL., vol. 53, no. 1, pages 583 - 594 *
LUO Z. ET AL.: "A PEPTIDE C-TERMINAL TO THE SECOND ZN FINGER OF HUMAN VITAMIN D RECEPTOR IS ABLE TO SPECIFY NUCLEAR LOCALIZATION.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 223, no. 2, pages 384 - 387 *

Also Published As

Publication number Publication date
AU2887195A (en) 1996-01-19
WO1996000087A2 (fr) 1996-01-04

Similar Documents

Publication Publication Date Title
CA2015060A1 (fr) Systeme de liberation d'anticorps pour modifier la reponse biologique
CA2249320A1 (fr) Anticorps humanises glycosyles specifiques des lymphocytes b
DE69531342D1 (de) Avidin-biotin immunokonjugate
AU563356B2 (en) Conjugate of enzyme and antibody
WO2000076550A3 (fr) Conjugue excipient-produit pharmaceutique
CA2134239A1 (fr) Procedes et composes de preciblage
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
CA2239167A1 (fr) Anticorp catalytique aldolase
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
WO1999066951A3 (fr) Utilisation d'anticorps bi-specifiques pour diagnostic et therapie de pre-ciblage
CA2215933A1 (fr) Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation
WO1999041273A3 (fr) Conjugues d'anp et d'adn et procedes de preparation desdits conjugues
CA2158054A1 (fr) Conjugues de proteines et de ligands bifonctionnels
WO1998023646A3 (fr) Agents de liaison specifiques d'un recepteur d'iga
CA2067244A1 (fr) Anticorps monoclonal specifique pour recepteur d'iga
AU2002303181A1 (en) Morpholino imaging and therapy
WO1998009647A3 (fr) Compositions de cyanidine et leurs usages therapeutiques et diagnostiques
CA2348026A1 (fr) Anticorps anti-semp1, methodes de production et utilisations connexes
WO1999040214A3 (fr) Vehicules d'apport d'acide nucleique
WO1996000087A3 (fr) Materiel de preciblage et nouveaux conjugues de preciblage
CA2286296A1 (fr) Inhibiteurs pour le recepteur de l'urokinase
EP0453097A3 (fr) Composition comprenant au moins deux anticorps differents ou leurs fragments
GB8927230D0 (en) Reagents
EP1023906A4 (fr) Potentialisateur pour anticorps anti-tumeur lymphoide
WO2003033653A3 (fr) Agents d'augmentation de l'affinite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase